Compound ID | 2889
F598
Class: Monoclonal antibody
| Spectrum of activity: | Gram-positive & Gram-negative |
| Details of activity: | Broad-spectrum activity; targets poly-N-acetyl-d-glucosamine (PNAG) in microbial surfaces and biofilms |
| Description: | Human monoclonal antibody; does not react to human tissues and organs (no cross-reactivity to human polysaccharides) |
| Institute where first reported: | Alopexx Pharmaceuticals, LLC |
| Year first mentioned: | 2013 |
| Highest developmental phase: | Phase 2 (NCT03222401) |
| Development status: | Active as of 2024 |
| External links: | |
| Guide to Pharmacology: | F598 |
| Main Source: | https://www.pnas.org/doi/full/10.1073/pnas.1303573110 |
| Citation: | https://www.sciencedirect.com/science/article/pii/S0021925820409834?via%3Dihub |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us.
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.